Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talacotuzumab or Daratumumab in MDS
NCT03011034Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of talacotuzumab, daratumumab in myelodysplastic syndromes (MDS), sponsored by Janssen Pharmaceutical. Started Feb 2017; status: completed.
02
Drugs
talacotuzumabdaratumumab
03
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT03011034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011034.